Short answer
Colgate-Palmolive (CL) filed an 8-K current report with the SEC on March 12, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). New board member: Christopher Boerner, Ph.D., 55; current Board Chair & CEO of Bristol-Myers Squibb, joins CL board effective March 15, 2026.
Colgate-Palmolive 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- New board member: Christopher Boerner, Ph.D., 55; current Board Chair & CEO of Bristol-Myers Squibb, joins CL board effective March 15, 2026
- Boerner brings global pharma/healthcare leadership; previously BMS COO, CCO, and earlier roles at Seattle Genetics, Genentech, McKinsey
- Compensation under standard non-employee director program per March 2025 proxy: no special or elevated pay package
- Board departure: Steven Cahillane will not stand for reelection at May 8, 2026 annual meeting due to new role as CEO of Kraft Heinz
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Colgate-Palmolive 8-K filings
Get the next CL 8-K as it lands
Follow CL for push alerts, or ask the research agent what this filing means.